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Abstract The antigen stimulation of RBL-2H3 cells induced
interleukin 13 (IL-13) production, which was inhibited by the
steroidal anti-in£ammatory drug dexamethasone and by the
c-Jun N-terminal kinase (JNK) inhibitor SP600125. Dexa-
methasone did not inhibit the antigen-induced phosphorylation
of JNK but inhibited that of c-Jun. In a cell-free system, the
phosphorylation of glutathione S-transferase-fused c-Jun by re-
combinant JNK was not inhibited by dexamethasone but was
inhibited by the addition of recombinant glucocorticoid receptor
(GR). These ¢ndings suggest that the inhibition of antigen-in-
duced IL-13 production by dexamethasone is due to the GR-
mediated inhibition of c-Jun phosphorylation induced by JNK.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Glucocorticoids are widely used for the treatment of in£am-
matory diseases such as asthma, rheumatoid arthritis and
autoimmune diseases. The most striking e¡ect of glucocorti-
coids is the inhibition of the expression of in£ammatory gene
products, which include cytokines, enzymes and adhesion
molecules [1]. Interleukin 13 (IL-13) is one of the cytokines
produced by mast cells and plays critical roles in remodeling
of the airway in an experimental model of asthma [2]. The
inhibition by glucocorticoids of IL-13 production in mast cells
[3] is considered critical to the anti-asthmatic e¡ects of gluco-
corticoids on mast cells although the inhibitory mechanism
has not been fully clari¢ed. The IL-13 promoter contains
the binding sites for the transcription factors GATA-3,
nuclear factor of activated T cells and activating protein-1
(AP-1) [4]. Glucocorticoids bind to the glucocorticoid receptor
(GR) and modulate gene expression either by direct binding
of the glucocorticoid^GR complex to the glucocorticoid-re-
sponsive element or indirectly by inhibiting the activities of
other transcription factors such as AP-1 [1].
A major component of AP-1 is a heterodimer of c-Jun and
c-Fos. The phosphorylation of c-Jun at Ser63 and Ser73 by
c-Jun N-terminal kinase (JNK) enhances AP-1 activity [5].
Several mechanisms by which glucocorticoids inhibit AP-1
activity are proposed: (1) inhibition of the binding of AP-1
to DNA by direct binding of GR to AP-1 [6^8]; (2) compet-
itive reduction of the interaction between AP-1 and the tran-
scriptional coactivator CREB binding protein (CBP) or p300
via the interaction of GR with CBP/p300 [9] ; (3) suppression
of the activation of JNK [10^12]; and (4) induction of the
inhibitory protein, glucocorticoid-induced leucine zipper [13].
However, there are several reports opposing these hypotheses
[14^17]. In this study, we examined the e¡ect of dexametha-
sone on the activation of AP-1 in connection with the inhibi-
tion of IL-13 production in the rat basophilic leukemia cell
line RBL-2H3. We found that dexamethasone inhibits the
antigen-induced phosphorylation of c-Jun without inhibiting
the activation of JNK, and proposed a novel mechanism by
which dexamethasone inhibits AP-1 activation in RBL-2H3
cells.
2. Materials and methods
2.1. Cell culture
Rat basophilic leukemia RBL-2H3 cells (Health Science Research
Resources Bank, Osaka, Japan) (2U105 cells/well in a 24-well cluster
dish, or 1U106 cells/well in a 6-well cluster dish) were incubated over-
night in Eagle’s minimal essential medium (EMEM) containing 10%
(v/v) fetal bovine serum (FBS, Sigma Chemical, St. Louis, MO, USA),
and 0.1% (v/v) conditioned medium of dinitrophenol (DNP)-speci¢c
IgE-producing hybridoma (kindly supplied by Dr. Kazutaka Maeya-
ma, Ehime University, Ehime, Japan).
2.2. Drug treatment
Dexamethasone (Sigma), the JNK inhibitor SP600125 (Biomol,
Plymouth Meeting, PA, USA), the p38 mitogen-activated protein
(MAP) kinase inhibitor SB203580 (Calbiochem-Novabiochem, San
Diego, CA, USA) and the MAP extracellular signal-regulated kinase
kinase (MEK) inhibitor PD98059 (New England Biolabs, Beverly,
MA, USA) dissolved in dimethylsulfoxide (DMSO) were diluted
with EMEM. After overnight incubation of the cells (2U105 cells)
in the presence of DNP-speci¢c IgE, the medium was changed to
0.4 ml of EMEM containing 5% (v/v) FBS in the presence or absence
of the antigen DNP-conjugated human serum albumin (HSA) (Sigma
Chemical) (50 ng/ml), dexamethasone and/or the JNK inhibitor
SP600125 at the concentration indicated and the cells were then in-
cubated for speci¢c periods. For the pretreatment of the cells
with SB203580 and PD98059, the cells were incubated in 0.36 ml of
the medium containing SB203580 (10 WM) or PD98059 (10 WM) for
10 min. The cells were then stimulated by the addition of 0.04 ml of
the medium containing the antigen (500 ng/ml) and 10 WM of the
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corresponding inhibitor into each well, and further incubated for 4 h.
The ¢nal concentration of DMSO was adjusted to be 0.2% (v/v).
2.3. Measurement of IL-13
After the antigen stimulation, the conditioned medium was col-
lected and centrifuged at 450Ug and 37‡C for 5 min. The IL-13 level
in the supernatant fraction was determined using a rat IL-13 ELISA
kit (BioSource, Camarillo, CA, USA).
2.4. Immunoblotting
After the antigen stimulation, the cells (5U106 cells/well in a 6-well
cluster dish) were lysed in 150 Wl of a lysis bu¡er (20 mM HEPES, pH
7.3, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 1 mM EDTA, 50 mM
NaF, 2.5 mM p-nitrophenylphosphate, 10 Wg/ml phenylmethylsulfonyl
£uoride, 1 mM Na3VO4 and 5 Wg/ml leupeptin). The cell lysate was
then sonicated for 1 min using a Handy Sonic Disruptor (Model UR-
20P, Tomy Seiko, Tokyo, Japan). Proteins in the cell lysate were
separated by electrophoresis on sodium dodecyl sulfate^polyacryl-
amide gel and transferred to a nitrocellulose membrane (Schleicher
and Schuell, Dassel, Germany). The levels of c-Jun, phospho-c-Jun,
JNK, phospho-JNK and actin were determined by immunoblotting
using polyclonal antibodies against the epitope corresponding to ami-
no acids 1^79 mapping at the amino-terminus of c-Jun (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), c-Jun phosphorylated at Ser73
(New England Biolabs), full-length JNK2 (Santa Cruz Biotechnol-
ogy), JNK phosphorylated at Thr183 and Tyr185 (Promega, Madison,
WI, USA), and the epitope mapping at the carboxy-terminus of actin
(Santa Cruz Biotechnology), respectively.
2.5. Preparation of glutathione S-transferase (GST)-fused c-Jun
The rat c-Jun cDNA was ampli¢ed by polymerase chain reaction
(PCR) using pBSrc-Jun-1 (Riken Gene Bank, Tsukuba, Japan) as a
template and the following primers, 5P-GGATCCATGACTGCA-
AAGATGGAAA-3P (sense) and 5P-GAATTCTCAAAACGTTTG-
CAACT-3P (antisense), containing a BamHI and EcoRI overhang,
respectively. The PCR products were digested with BamHI and
EcoRI, and inserted into pGEX4T (Amersham Pharmacia Biotech,
Uppsala, Sweden). pGEX4T-c-Jun was introduced into Escherichia
coli DH5K and recombinant GST-c-Jun was expressed by incubation
for 4 h at 25‡C in the presence of 0.5 mM of isopropyl-L-D-galacto-
pyranoside (Takara, Kyoto, Japan). The recombinant GST-c-Jun was
puri¢ed using glutathione-Sepharose beads (Amersham Pharmacia
Biotech).
2.6. Analysis of JNK activity
GST-c-Jun-immobilized glutathione-Sepharose beads (50% (v/v)
gel, 20 Wl) and JNK (0.25 pmol, Upstate Biotechnology, Lake Placid,
NY, USA) were incubated for 20 min at 37‡C in the presence or
absence of GR (0.05^0.25 pmol, Panvera, Madison, WI, USA), bo-
vine serum albumin (BSA, fraction V, 10 nmol, Wako Pure Chem-
icals, Tokyo, Japan) and dexamethasone (100 nM, Sigma) in 50 Wl of
assay bu¡er (20 mM HEPES, pH 7.8, 20 mM MgCl2 and 20 mM
L-glycerophosphate) containing 10 mM ATP (Sigma). After the incu-
bation, GST-c-Jun-immobilized glutathione-Sepharose beads were
washed with 0.5 ml of phosphate-bu¡ered saline (pH 7.4) three times.
GST-c-Jun was eluted with sample bu¡er (50 mM Tris^HCl, pH 6.8,
2% (w/v) sodium dodecyl sulfate, 850 mM 2-mercaptoethanol and
10% (v/v) glycerol) and the phosphorylation of GST-c-Jun was deter-
mined by immunoblotting as described above.
2.7. Statistical analysis
Results were analyzed for statistical signi¢cance using Student’s
t-test for unpaired observations.
3. Results
3.1. E¡ects of dexamethasone on the antigen-induced IL-13
production
The antigen stimulation of IgE-sensitized RBL-2H3 cells
induced IL-13 production at 4 h (Fig. 1A). The simultaneous
addition of dexamethasone (1, 10, and 100 nM) with the anti-
gen decreased the IL-13 level in the conditioned medium at
4 h in a concentration-dependent manner (Fig. 1A). The
inhibition by dexamethasone was observed from 1 to 4 h
(Fig. 1B).
3.2. E¡ects of MAP kinase inhibitors on the antigen-induced
c-Jun phosphorylation and IL-13 production
To clarify the involvement of JNK in the antigen-induced
IL-13 production, we examined the e¡ect of the JNK inhibitor
SP600125. Stimulation with the antigen for 1 h increased both
the phosphorylation and the protein production of c-Jun,
which were inhibited by SP600125 (20 and 40 WM) in a con-
centration-dependent manner (Fig. 2A). Equal loading of pro-
teins on all lanes was con¢rmed by blotting with anti-actin
antibody. In the same concentration range, SP600125 inhib-
ited the antigen-induced IL-13 production at 4 h (Fig. 2B). In
contrast, the p38 MAP kinase inhibitor SB203580 (10 WM)
and the MEK inhibitor PD98059 (10 WM) did not inhibit
the antigen-induced production of IL-13 (Fig. 2C).
3.3. E¡ects of dexamethasone on the antigen-induced
phosphorylation of c-Jun and JNK and their protein levels
The antigen-induced increase in the phosphorylation and
the protein level of c-Jun reached a maximum 60 min after
the antigen stimulation (Fig. 3). Simultaneous treatment with
dexamethasone (100 nM) and the antigen decreased both the
antigen-induced increase in the levels of c-Jun phosphoryla-
Fig. 1. E¡ects of dexamethasone on the antigen-induced IL-13 production. IgE-sensitized RBL-2H3 cells (2U105 cells) were stimulated with
DNP-HSA (50 ng/ml) in 0.4 ml of medium in the presence of the indicated concentrations of dexamethasone (Dex) for 4 h (A) or for the peri-
ods indicated (B). The IL-13 concentration in the conditioned medium was determined by ELISA. Vertical bars represent S.E.M. from three
wells. Statistical signi¢cance: **P6 0.01 and ***P6 0.001 vs. DNP-HSA alone, ###P6 0.001 vs. non-stimulated control. N.D., not detectable
(6 1.5 pg/ml).
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tion and c-Jun protein (Fig. 3), but did not a¡ect the antigen-
induced increases in the phosphorylation of JNK 1 and JNK
2, which attained a maximum 30 min after the stimulation
(Fig. 4). The protein levels of each JNK did not change on
treatment with the antigen in the presence or absence of dexa-
methasone (Fig. 4).
3.4. E¡ects of GR on JNK-induced phosphorylation of
GST-c-Jun
Incubation of GST-c-Jun-immobilized glutathione-Sephar-
ose beads with recombinant JNK (rJNK, 0.25 pmol) in the
assay bu¡er containing 10 mM ATP induced the phosphory-
lation of GST-c-Jun (Fig. 5A). The phosphorylation of GST-
Fig. 2. E¡ects of SP600125 on the antigen-induced c-Jun phosphorylation and IL-13 production. A: IgE-sensitized RBL-2H3 cells (1U106 cells)
were stimulated with DNP-HSA (50 ng/ml) in 2 ml of medium in the presence of the indicated concentrations of SP600125 for 1 h. c-Jun,
phospho-c-Jun and actin in the cell lysate were detected by immunoblotting. B: IgE-sensitized RBL-2H3 cells (2U105 cells) were stimulated
with DNP-HSA (50 ng/ml) in 0.4 ml of medium in the presence of the indicated concentrations of SP600125 for 4 h. The IL-13 concentration
in the conditioned medium was determined by ELISA. Vertical bars represent S.E.M. from three wells. Statistical signi¢cance: ***P6 0.001 vs.
DNP-HSA alone. N.D., not detectable (6 1.5 pg/ml). C: IgE-sensitized RBL-2H3 cells (2U105 cells) were preincubated for 10 min in 0.36 ml
of medium in the presence or absence of SB203580 (SB, 10 WM) or PD98059 (PD, 10 WM). The cells were then stimulated with DNP-HSA (50
ng/ml) for 4 h in 0.4 ml of medium in the presence of the corresponding drugs or SP600125 (SP, 40 WM). The IL-13 concentration in the con-
ditioned medium was determined by ELISA. Vertical bars represent S.E.M. from three wells. Statistical signi¢cance: ***P6 0.001 vs. DNP-
HSA alone.
Fig. 3. Inhibition of the antigen-induced phosphorylation and expression of c-Jun by dexamethasone. IgE-sensitized RBL-2H3 cells (1U106
cells) were stimulated with DNP-HSA (50 ng/ml) in 2 ml of medium in the presence (+) or absence (3) of dexamethasone (Dex, 100 nM) for
the periods indicated. c-Jun and phospho-c-Jun were detected by immunoblotting (A). The levels of c-Jun and phospho-c-Jun were determined
by densitometric analysis (B). The density at time 0 in Dex (3) is set to 1.0.
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c-Jun by rJNK was not inhibited by dexamethasone (100 nM)
but was inhibited by recombinant GR (rGR, 0.25 pmol) in the
presence or absence of the ligand dexamethasone (Fig. 5A).
The addition of BSA instead of rGR did not a¡ect the JNK
activity (Fig. 5A). rGR inhibited the rJNK-induced phosphor-
ylation of GST-c-Jun in a concentration-dependent manner,
and at 0.25 pmol, the same concentration as JNK, the stron-
gest inhibitory e¡ect was observed (Fig. 5B).
4. Discussion
Re£ecting that the IL-13 promoter region contains the AP-1
binding site [4], the antigen-induced IL-13 production in
RBL-2H3 cells was highly dependent on the phosphorylation
of c-Jun, a component of AP-1, by JNK (Fig. 2B), but not
regulated by p44/42 ERK MAP kinase and p38 MAP kinase
(Fig. 2C). Dexamethasone reduced the antigen-induced phos-
Fig. 4. E¡ects of dexamethasone on the antigen-induced phosphorylation of JNK. IgE-sensitized RBL-2H3 cells (1U106 cells) were stimulated
with DNP-HSA (50 ng/ml) in 2 ml of medium in the presence (+) or absence (3) of dexamethasone (Dex, 100 nM) for the periods indicated.
JNK 1, JNK 2, phospho-JNK 1 and phospho-JNK 2 were detected by immunoblotting. The levels of JNK 1, JNK 2, phospho-JNK 1 and
phospho-JNK 2 were determined by densitometric analysis. The density at time 0 in Dex (3) is set to 1.0.
Fig. 5. Inhibition by rGR of rJNK-induced phosphorylation of GST-c-Jun. A,B: GST-c-Jun-immobilized glutathione-Sepharose beads and
rJNK (0.25 pmol) were incubated in 50 Wl of the assay bu¡er containing 10 mM ATP for 20 min at 30‡C in the presence (+) or absence (3)
of BSA (10 nmol), dexamethasone (Dex, 100 nM) and/or rGR (0.25 pmol (A) or the amount indicated (B)). GST-c-Jun and phospho-GST-c-
Jun were detected by immunoblotting.
FEBS 27834 5-11-03
N. Hirasawa et al./FEBS Letters 554 (2003) 489^493492
phorylation of c-Jun (Fig. 3), suggesting that the inhibition of
the antigen-induced IL-13 production by dexamethasone is
mediated by the inhibition of the antigen-induced activation
of AP-1. Furthermore, the antigen-induced increase in the
c-Jun protein level was suppressed by SP600125 (Fig. 2A)
and dexamethasone (Fig. 3), indicating that the expression
of c-Jun is also regulated by the phosphorylation of c-Jun.
We reported that dexamethasone inhibited the antigen-in-
duced activation of p44/42 MAP kinase [18] and JNK [12] in
RBL-2H3 cells, but in both cases, preincubation with dexa-
methasone for 6 h or more was required. In addition, the
inhibition by dexamethasone of the antigen-induced degranu-
lation and arachidonic acid release in RBL-2H3 cells also
required preincubation with dexamethasone for several hours
[12]. However, in this study, we demonstrated that dexame-
thasone inhibited the antigen-induced production of IL-13
without preincubation. We also found that simultaneous
treatment with dexamethasone inhibited the antigen-induced
phosphorylation of c-Jun without inhibiting that of JNK, i.e.
the activation of JNK. Similar results were also observed in
the murine macrophage cell line RAW 264.7. Namely, when
RAW 264.7 cells were stimulated by lipopolysaccharide (1 Wg/
ml) in the presence of dexamethasone (100 nM), the lipopoly-
saccharide-induced phosphorylation of c-Jun was reduced by
dexamethasone at 1 h, but that of JNK at 20 min was not
inhibited (data not shown). Because the antigen-induced
translocation of JNK to the nucleus is not inhibited by dexa-
methasone [19], it is likely that dexamethasone inhibits c-Jun
phosphorylation via inhibition of JNK activity. In a cell-free
system using recombinant proteins, we disclosed that the
phosphorylation of GST-c-Jun by rJNK was not inhibited
by dexamethasone but was inhibited by rGR (Fig. 5A). Fur-
thermore, dexamethasone, the ligand of GR, was not neces-
sary for the rGR-mediated inhibition of JNK activity (Fig.
5A). These ¢ndings suggested that GR was translocated into
the nucleus by dexamethasone and interfered with the associ-
ation of activated JNK with c-Jun.
It is reported that GR binds to c-Jun thereby preventing
c-Jun from binding to DNA [6^8] and/or a coactivator such as
p300/CBP [9]. Taken together, we hypothesized that GR dis-
rupts the binding of JNK to c-Jun to inhibit the phosphory-
lation of c-Jun by JNK. In addition, because GR is phosphor-
ylated by JNK [20], the interaction between GR and JNK
might be involved in the inhibition of the phosphorylation
of c-Jun. The molecular mechanisms involved are under in-
vestigation in our laboratory.
In conclusion, dexamethasone inhibited AP-1-mediated IL-
13 production through GR-mediated inhibition of c-Jun phos-
phorylation. The inhibition by GR of the phosphorylation of
c-Jun by JNK is a novel mechanism by which glucocorticoids
inhibit the activation of AP-1.
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